Search results for "biologic"
Article
Current Innovations and Practices To Address Microbial Contamination in Downstream Bioprocessing
Bioburden control is an area of serious concern for anyone making mAbs or other biologicals. Manufacturers’ efforts to avoid microbial contamination are today being complemented by development…
Article
How to Address Bioburden Challenges: Insights and Tips
Bioburden control is an area of serious concern for anyone making mAbs or other biologicals. Manufacturers’ efforts to avoid microbial contamination are today being complemented by developments from…
Article
The New World of Biopharmaceutical Manufacturing
Industry experts discuss the single-use revolution and changes to upstream and downstream processing equipment.
By Jennifer Markarian
…
Article
From Darwin to Recombinant Fc Multimers
Fabian Käsermann from CSL Behring Switzerland talked further about the Fc multimers, and the biochemical and biological properties of these recombinant Fc hexamers. As discussed during the presentatio…
Article
Fusion Proteins Pose Manufacturability Challenges
New design strategies
While fusion proteins are a growing segment of the biologics market, manufacturing gaps do remain that must be addressed. Specific concerns for Chamow, as outlined previously…
Article
Speed and Flexibility Are Dual Goals for Biopharma Operations
What trends did the BioPharm International editorial team observe about manufacturing facilities and operations?
As demand for biologics drug manufacturing increases capacity, contract manufacture…
Article
Automating Processes in Upstream Processing
…ocess control system (DCS/PCS) continues to be the technology of choice for most companies in large biologics facilities. Typical vendors would be Siemens PCS 7, Emerson DeltaV, Rockwell PlantPax, an…
Article
A Q&A with Eric Langer: CMOs Embrace New Technology
We also note that many biologics will require larger volumes that may not be appropriate to what is currently considered a typical max volume (e.g., ~2000 liter) for single-use scales.
Presently, ab…
Article
Generating a Fully Processed Antibody
About the Authors
Gregory Bleck is global head of R&D biologics; Dona York is director of upstream process development; and David Rabuka is global head of R&D chemical biology, all at Catalent.
Article
A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
Similar to the single-use system advances, continuous manufacturing for the production of biologics is showing some step-by-step advances, but still trails advances on the small-molecule market.
I…